HumaScan
This article was originally published in The Gray Sheet
Executive Summary
Donald Brounstein resigns as president and CEO of the Cranford, New Jersey firm May 19. Since founding the company in 1995, Brounstein managed the development and recent launch of the firm's Breast Alert breast cancer detection device ("The Gray Sheet" Nov. 17, In Brief). Elizabeth Tallett replaces Brounstein on an interim basis as chairman and acting CEO until a permanent replacement is found. Tallett maintains responsibilities as president and CEO of two start-up companies: Dioscor, a biotech management company and Ellard Pharmaceuticals...
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.